Skip to search formSkip to main contentSkip to account menu

ocrelizumab

Known as: rhuMAb 2H7 
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Antibodies, Monoclonal, Humanized
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

PR 070769

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Ocrelizumab shorter infusion
  • H. Hartung
  • Neurology: Neuroimmunology & Neuroinflammation
  • 2020
  • Corpus ID: 219397860
Objective To assess the safety of ocrelizumab (OCR) shorter duration infusion in patients with MS. Methods ENSEMBLE PLUS is a… 
2018
2018
Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis.
2017
2017
B-cells as therapeutic targets in neuro-inflammatory diseases.
Review
2016
Review
2016
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
PURPOSE OF REVIEW The review discusses future directions in research on multiple sclerosis and neuromyelitis optica, as long-held… 
Review
2014
Review
2014
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple… 
Review
2014
Review
2014
Future treatment approaches to multiple sclerosis.
Review
2013
Review
2013
An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Disease-modifying therapies (DMTs), known to actively reduce relapses and delay disability progression, have been used for the… 
Review
2010
Review
2010
Diversity in antibody-based approaches to non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of… 
2009
2009
Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way.
Abstract 3726 Poster Board III-662 CD20 is a specific cell surface marker found on normal as well as malignant B cells. Rituximab… 
2007
2007
Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.
Background: Ocrelizumab is a new humanised anti-CD20 antibody with the potential for enhanced efficacy in non-Hodgkin’s lymphoma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)